Single Center Experience with a 4-Week 177Lu-PSMA-617 Treatment Interval in Patients with Metastatic Castration-Resistant Prostate Cancer
暂无分享,去创建一个
J. Kononen | A. Kangasmäki | T. Joensuu | K. Kairemo | J. Kemppainen | S. Malaspina | Bernd Pape | J. Jalomäki
[1] H. Beltran,et al. A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer , 2022, The Journal of clinical investigation.
[2] M. Stockler,et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. , 2022, The Lancet. Oncology.
[3] K. Pienta,et al. 177Lu‐PSMA radioligand therapy effectiveness in metastatic castration‐resistant prostate cancer: An updated systematic review and meta‐analysis , 2022, The Prostate.
[4] K. Rahbar,et al. Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy , 2021, Theranostics.
[5] K. Rahbar,et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. , 2021, The New England journal of medicine.
[6] J. Czernin,et al. Mechanisms of Resistance to Prostate-Specific Membrane Antigen–Targeted Radioligand Therapy in a Mouse Model of Prostate Cancer , 2020, The Journal of Nuclear Medicine.
[7] K. Rahbar,et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[8] B. Hadaschik,et al. Prostate-specific membrane antigen targeted PET imaging for prostate cancer recurrence. , 2020, Current opinion in urology.
[9] K. Rahbar,et al. Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy , 2020, Theranostics.
[10] K. Rahbar,et al. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy , 2020, Theranostics.
[11] R. Fimmers,et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial) , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[12] K. Rahbar,et al. Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[13] W. Wadsak,et al. Clinical outcome of standardized 177Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[14] D. Murphy,et al. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer , 2019, The Journal of Nuclear Medicine.
[15] M. Stockler,et al. TheraP: a randomized phase 2 trial of 177Lu‐PSMA‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) , 2019, BJU international.
[16] W. Oyen,et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT) , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[17] U. Haberkorn,et al. Radionuclide Therapy of Metastatic Prostate Cancer. , 2019, Seminars in nuclear medicine.
[18] M. Schwaiger,et al. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.
[19] K. Rahbar,et al. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617 , 2019, Theranostics.
[20] R. Epstein,et al. Results of a Prospective Phase 2 Pilot Trial of 177Lu–PSMA‐617 Therapy for Metastatic Castration‐Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression , 2019, Clinical genitourinary cancer.
[21] Yong-il Kim,et al. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis , 2018, Clinical nuclear medicine.
[22] D. Murphy,et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[23] Rakesh Kumar,et al. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT. , 2018, Clinical nuclear medicine.
[24] U. Haberkorn,et al. Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq , 2018, The Journal of Nuclear Medicine.
[25] K. Rahbar,et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[26] R. Fimmers,et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy , 2017, Oncotarget.
[27] K. Kopka,et al. Procedures for the GMP-Compliant Production and Quality Control of [18F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer , 2017, Pharmaceuticals.
[28] K. Rahbar,et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[29] Rolf Fimmers,et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[30] R. Fimmers,et al. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617 , 2017, The Journal of Nuclear Medicine.
[31] W. Brenner,et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, Journal of Nuclear Medicine.
[32] M Essler,et al. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[33] E. Ozkan,et al. Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer. , 2016, Clinical nuclear medicine.
[34] J. Lavalaye,et al. GMP-compliant 68Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use , 2015, EJNMMI Research.
[35] Ximing J. Yang,et al. Neuroendocrine differentiation of prostate cancer: a review. , 2014, American journal of clinical and experimental urology.